Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Rheumatoid Arthritis (RA)
Interventions
DRUG

Tocilizumab + methotrexate(MTX)

Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week

DRUG

Tocilizumab placebo + methotrexate(MTX)

Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week

Trial Locations (12)

Unknown

Buddhist Dalin Tzu Chi General Hospital, Chiayi City

Chang Gung Memorial Hospital -Kaohsiung, Kaohsiung City

Kaohsiung Medical University Hospital, Kaohsiung City

Kaohsiung Veterans General Hospital, Kaohsiung City

Chung Shan Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

Cathay General Hospital, Taipei

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei

Chang Gung Memorial Hospital - Linkou, Taoyuan District

Sponsors
All Listed Sponsors
lead

Chugai Pharma Taiwan

INDUSTRY

NCT01258712 - Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients | Biotech Hunter | Biotech Hunter